07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Immuneering, Teva deal

Teva will acquire a 51% stake in Immuneering for $45 million. Immuneering analyzes genomic and proteomic data to generate hypotheses and design follow-up studies for compounds in development. Teva will receive exclusive right of first...
00:53 , Aug 4, 2015 |  BC Extra  |  Company News

Teva buying majority stake in Immuneering

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire a 51% stake in computational genomic analysis company Immuneering Corp. (Cambridge, Mass.). Teva spokesperson Denise Bradley said Teva will pay Immunoneering $45 million in three tranches, and will...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Immuneering, Bristol-Myers deal

The companies expanded an existing deal using Immuneering's computational biology methods to assist Bristol-Myers' drug development. Immuneering declined to disclose details, and Bristol-Myers could not be reached. Immuneering analyzes genetic, genomic and proteomic data to...